The ESSENCE of hope: what semaglutide's Food and Drug Administration approval means [PMID: 41983226] Laboratory literature summary: The ESSENCE of hope: what semaglutide's Food and Drug Administration approval means for metabolic dysfunction-associated steatohepatitis
As previously reported, the reduction of inflammation may be related to weight loss, that was significant in the different outcome trials, going from a 0.6-kg reduction at 12 weeks with Lixisenatide in ELIXA trial to 4.3 kg at 2 years with injectable semaglutide in SUSTAIN-6 trial [25, 26]
While cartilage health matters, joint function depends on more than cartilage
Adults aged 20 years or older diagnosed with T2DM between 2016 and 2024 were included if they received any hypoglycemic agents within 3 months before and after diagnosis
Integrated Regenerative Environment By simultaneously addressing immune signaling, cellular migration, vascular support, and matrix remodeling, KLOW promotes coordinated biological renewal rather than isolated or short-lived effects
Sleep and recovery DSIP (Delta Sleep-Inducing Peptide) Studied for sleep architecture and stress response